421
Participants
Start Date
September 9, 2020
Primary Completion Date
May 4, 2021
Study Completion Date
May 4, 2021
TP-03, 0.25%
TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
TP-03 Vehicle
Vehicle of TP-03 ophthalmic solution, administered twice a day
Scott & Christie and Associates, PC, Cranberry Township
Piedmont Eye Center, Lynchburg
Oculus Research, Inc at EyecareCenter, Raleigh
Vita Eye Clinic, Shelby
Total Eye Care, P.A., Memphis
The Eye Care Institute, Louisville
Washburn Research LLC, Indianapolis
Midwest Cornea Associates, LLC, Carmel
Ophthalmology Associates, St Louis
Vision Institute, Colorado Springs
Alpine Research Organization, Layton
Cornea and Cataract Consultants of Arizona, Phoenix
Eye Research Foundation, Newport Beach
Visionary Eye Institute, Newport Beach
Andover Eye Associates, Andover
Tarsus Pharmaceuticals, Inc.
INDUSTRY